uniQure N.V. (NASDAQ:QURE – Get Free Report) Director Robert Gut sold 7,552 shares of the business’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $26.05, for a total value of $196,729.60. Following the completion of the transaction, the director directly owned 27,435 shares of the company’s stock, valued at approximately $714,681.75. The trade was a 21.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Robert Gut also recently made the following trade(s):
- On Thursday, June 11th, Robert Gut sold 2,726 shares of uniQure stock. The stock was sold at an average price of $27.06, for a total value of $73,765.56.
uniQure Stock Up 2.8%
Shares of QURE traded up $0.75 during trading hours on Friday, hitting $27.57. The company had a trading volume of 835,627 shares, compared to its average volume of 2,601,234. The company has a market capitalization of $1.74 billion, a PE ratio of -7.92 and a beta of 0.98. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50. The company’s fifty day moving average price is $22.31 and its two-hundred day moving average price is $21.76.
Analyst Ratings Changes
Several research analysts recently weighed in on the company. Cantor Fitzgerald restated a “neutral” rating and set a $9.00 target price (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Leerink Partners restated an “outperform” rating and set a $35.00 target price on shares of uniQure in a research note on Monday, March 2nd. Sanford C. Bernstein downgraded uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Finally, Wolfe Research assumed coverage on uniQure in a research note on Monday, February 23rd. They set a “peer perform” rating on the stock. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, uniQure has an average rating of “Moderate Buy” and an average price target of $42.83.
Get Our Latest Report on uniQure
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC grew its stake in uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after buying an additional 1,705,556 shares during the last quarter. Aberdeen Group plc grew its stake in uniQure by 25.1% during the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after purchasing an additional 738,897 shares during the last quarter. State Street Corp grew its stake in uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after purchasing an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. grew its stake in uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after purchasing an additional 1,785,275 shares during the last quarter. Finally, Orbimed Advisors LLC grew its stake in uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after purchasing an additional 1,398,749 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.
uniQure Company Profile
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.
Read More
- Five stocks we like better than uniQure
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
